Physician profile
Ali A Hashmi
NPI 1336473172
$2,415.42
in general payments reported to CMS, 2019-2025
26 companies · $624 in 2025
The $624 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.07 · 2021: $52.71 · 2022: $569 · 2023: $585 · 2024: $573 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763 · Education: $19.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.60 |
| Education | $19.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,037.45 | 2021-2025 | |
| Medtronic, INC. | $235.53 | 2022-2024 | Pillcam |
| Janssen Biotech, INC. | $192.21 | 2022-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $126.70 | 2022 | |
| Celgene Corporation | $113.39 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $96.23 | 2023-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $80.50 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $78.54 | 2024-2025 | Voquezna |
| Genzyme Corporation | $73.41 | 2023-2025 | |
| Redhill Biopharma INC. | $51.73 | 2023-2025 | Talicia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.49 | 2022-2025 | Xifaxan |
| Terumo Medical Corporation | $29.16 | 2023 | Glidesheath Slender, Tr Band, Angio-Seal |
| Tersera Therapeutics LLC | $23.50 | 2024 | Quzyttir |
| Madrigal Pharmaceuticals | $22.39 | 2025 | Rezdiffra |
| Vivus LLC | $21.95 | 2023 | Pancreaze |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocon Biologics INC | $21.88 | 2025 | Hulio |
| Olympus America INC. | $21.56 | 2025 | Endoclot Phs |
| Shield Therapeutics INC | $20.67 | 2023 | Accrufer |
| Intercept Pharmaceuticals, INC. | $20.40 | 2025 | |
| Aimmune Therapeutics, INC. | $20.27 | 2025 | Vowst |
| Amgen INC. | $19.40 | 2025 | Uplizna |
| Celltrion USA INC. | $19.10 | 2024 | Zymfentra |
| Merck Sharp & Dohme LLC | $14.63 | 2023 | Dificid |
| Echosens North America, INC. | $13.30 | 2023 | Fibroscan |
| Sandoz INC. | $12.96 | 2023 | Hyrimoz |
| Mallinckrodt Enterprises LLC | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.